Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.56 |
| ▸ | FNTB | P49356 | 10/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31338812 | 0.91 | FNTA (0.54) | FNTAFNTBMAPTLMNATHRB | |
| SCHEMBL31338818 | 0.82 | FNTA (0.42) | FNTAFNTBMAPTLMNATHRB | |
| SCHEMBL27156298 | 0.79 | FNTA (0.53) | FNTAFNTBMAPTKDM4ENPSR1 | |
| SCHEMBL31338823 | 0.78 | ALDH1A1 (0.45) | MAPTLMNATHRBKDM4ENPSR1 | |
| SCHEMBL26931128 | 0.77 | FNTA (0.54) | FNTAFNTBMAPTLMNAKDM4E | |
| SCHEMBL27211517 | 0.72 | FNTA (0.52) | FNTAFNTBMAPTLMNAKDM4E | |
| SCHEMBL20917738 | 0.71 | FNTA (0.49) | FNTAFNTBMAPTLMNAKDM4E | |
| SCHEMBL27156309 | 0.71 | FNTA (0.52) | FNTAFNTBKDM4ENPSR1RXFP1 | |
| SCHEMBL27156308 | 0.71 | NOD2 (0.48) | FNTAFNTBLMNAKDM4ENPSR1 | |
| SCHEMBL24749043 | 0.70 | FNTA (0.44) | FNTAFNTBMAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12194029-B1 | Ethyl-1-(substitutedbenzoyl)-5-methylpyrrolo[1,2-a]quinoline-3-carboxylates as anticancer agents | King Faisal University (SA) | 2025-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194029-B1 | Ethyl-1-(substitutedbenzoyl)-5-methylpyrrolo[1,2-a]quinoline-3-carboxylates as anticancer agents | TOP2A, TOP1, TP53 | FNTA 3870/4885FNTB 3906/4885MAPT 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.